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Adult—onset minimal change nephrotic syndrome: a long—term follow—
up. A series of 89 adult—onset nephrotic patients with minimal changes
on renal biopsy was analyzed to compare the rate of response to
corticosteroids and cytotoxic agents and the stability of remission or
frequency of relapses at different ages. Severe hypertension and dimin-
ished renal function were more common in patients aged over 60 years,
who formed 22.5% of the group. Seventy—five patients were given a first
course of prednisolone in an initial dose of 60 mg124 hr. After an eight
week course of tapering doses of corticosteroids, only 45 of the 75
patients were in complete remission, 55 patients after 16 weeks and
eventually 58 lost their proteinuria. The respective estimates of remis-
sion were 60%, 76% and 81%. Subsequently, of the 58 treated patients
who responded, 24% never relapsed. Fifty—six percent of the patients
relapsed on a single occasion or infrequently, and only 21% were
frequent relapsers. Cyclophosphamide was used in 36 patients, in two
as initial treatment, in II because of corticosteroid resistance, and in
the remainder because of relapses. The time—course of loss of protein-
uria was similar to that following treatment with corticosteroids, 25
(69%) losing proteinuria within 16 weeks. Only four patients failed to
lose their nephrotic syndrome. Two of them had presented in acute
renal failure and all four were over 60 years of age. The stability of
remission after cyclophosphamide was better than that reported for
children, only 13 of 36 showing relapses and 66% being in remission at
five years, after which no further relapses were seen. Of the whole
group (89), at the most recent follow—up, only 13 patients still had active
disease and only five were nephrotic (6%). Mortality was confined to
older patients; only 5 of IS deaths were the result of complications of
the nephrotic syndrome, and the rest incidental. Thus, although adults
with a minimal change nephrotic syndrome resemble children with this
condition in many respects, they go into acute renal failure more
frequently, have hypertension or diminished renal function more often,
respond more slowly and slightly less often to both corticosteroids and
cytotoxic agents, but relapse less frequently and have more stable
remissions after cyclophosphamide treatment.
It is well known that the majority of children with a nephrotic
syndrome show only minimal changes in their renal biopsy,
approximately 77% in the large group of the International Study
of Kidney Disease in Children [1, 2]. Typically, such patients
respond within weeks to treatment with corticosteroids [2, 3],
and their subsequent course has been described in detail [4—8].
More than half of such patients will relapse, some of them
repeatedly, and these patients may benefit from courses of
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alkylating agents such as cyclosphosphamide [7—12] or chior-
ambucil [13—15]. Progression to end—stage renal failure, al-
though it has been described in occasional steroid—responsive
minimal change nephrotic children, is extremely rare [16—18].
As many as 25 to 30% of adult nephrotics also show a minimal
change pattern on renal biopsy [19, 20] and the majority seem,
as in childhood, initially responsive to corticosteroids [19—24].
However, the rate of response to corticosteroids, subsequent
response to cytotoxic agents, and long—term follow—up have not
been established as for the childhood patients. Also, the uni-
versal practice of renal biopsy in adult nephrotic patients before
any treatment is begun has been criticized recently [25, 26]. If
the alternative approach is to be adopted, that of "blind"
corticosteroid treatment with biopsy only in resistant cases,
then data on the time—course of response in adult minimal
change nephrotics are required to time the subsequent biopsy;
such data are not available.
We reviewed the adult—onset nephrotic patients with a min-
imal change histology seen in our unit from 1963 to 1982. This
report extends and amplifies a paper published 10 years ago
[21]. In the present report, 89 patients are included with a
follow—up ranging up to 24 years (mean 7.5 years). We present
data describing in detail for the first time the timing of response
to corticosteroids and cyclophosphamide, the stability of remis-
sion and long—term outcome, in adult nephrotics with minimal
change disease.
Methods
Definitions
A nephrotic syndrome. A nephrotic syndrome was defined as
the presence of edema, proteinuria in excess of 3 g/24hr and a
serum albumin less than 30 g/liter.
A remission. Remission was defined as complete when loss of
edema and return of proteinuria to the normal range was
obtained (< 0.3 g124 hr), or as partial if there was loss of edema
but persistence of proteinuria in the range of 0.3 to 3.0 g/24 hr.
A relapse. Relapse was defined as reappearance of protein-
uria for more than one week, with or without edema.
Acute renal failure. ARF was defined as oliguria associated
with a rapid and persistent decline in renal function to a GFR of
 20 muter/mm, plasma creatinine  250 .tmole/liter, and/or
urea  30 mmole/liter.
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Renal impairment. Renal impairment was defined as a sus-
tained decrease in renal function (more than six months),
associated with a creatinine above 150 mole/liter, urea  10
mmole/liter or GFR 50 mliter/min/l.73m2.
Definition of the pattern of relapses is difficult. We used the
following definitions: A frequentb' relapsing ("frequent relap-
ser") course was defined by two or more relapses within the
first six months after a steroid—induced remission, or four or
more within the first year.
A steroid—dependent course was defined as (a) two consecu-
tive relapses appearing when the steroid dose was decreased or
stopped, or (b) relapse within the first month after treatment
was discontinued (early relapser).
Occasional or infrequent relapsers were defined as those who
relapsed only once (single) or more (multiple), but did not
satisfy any of the previous definitions.
Patients
Between 1963 and July 1982, 408 patients with a nephrotic
syndrome were studied, and most were followed up at Guy's
Hospital.
Ninety one patients (22%) had biopsies which satisfied crite-
ria for minimal change glomerular lesion, as we have defined in
previous reports [21, 22]. Two patients were excluded from
analysis on the basis of inadequate follow—up.
All the remaining 89 patients had the apparent onset of their
disease when aged 15 or more. None had a past history of a
nephrotic syndrome or other renal disease, except one patient
who had had a left nephrectomy aged 50 (20 years before the
appearance of his nephrotic syndrome) for a carcinoma of the
kidney.
Renal biopsies were performed in the prone position with a
Vim—Silverman or Becton Dickinson biopsy needle. Tissue was
processed as described previously [21] for optical microscopy.
From 1970, sections of plastic—embedded material stained with
tolouidine blue were examined for the presence of deposits.
From 1972, cryostat sections of frozen material were routinely
stained with a variety of peroxidase or fluorescent—conjugated
antisera [27].
Protein excretion was measured by the biuret method, urea
using the standard Auto Analyzer 12-channel technique, creat-
mine by a rate—dependent method on an LKB analyzer. Gb-
merular filtration rates were determined by the 51Cr-EDTA
method of Chantler et al [281.
Treatment
Corticosteroid courses usually varied in duration from eight
to 20 weeks (see results sections), but 11 patients received more
prolonged courses. Prednisone was given in a dose of 60
mg/24hr (1 mg/kg/24hr) for the first week, decreasing to 45 mg
(0.75 mg/kg)/24hr in the second week and thereafter for a
further four weeks. On three occasions betamethasone or
ACTH were used instead of prednisone. Data from these
patients have been included in the analysis of the
corticosteroid—treated patients. In three severely nephrotic
patients with acute renal failure, I g intravenous pulses of
methylprednisolone were given before the biopsy result was
known.
Since 1970, cyclophosphamide was used at a dose of 3
mg/kgl24hr given for eight weeks, Before 1970, three patients
were given more intense and more prolonged treatment at an
initial dose of 5 mg/kg/24hr until leukopenia appeared [12]. In
some patients prednisone was given concomitantly for eight
weeks, in others it was used alone (Results),
Azathioprine was used in four patients along with cortico-
steroids. As part of a trial [20], two patients received one years
treatment with combination. The results of these four patients
treated with azathioprine have not been included in the analysis
of the corticosteroid—treated group.
General management
Besides these supposedly specific treatments, patients re-
ceived a high protein diet (> 100 g/24hr), diuretics usually in
moderate dosages after the acute episode, and intravenous
albumin and intravenous furosemide if very edematous, espe-
cially within the past ten years. Over the past 15 years also, we
have routinely used subcutaneous heparin 5,000 i.u. subcuta-
neously in edematous nephrotic patients in the hospital.
Results
Of the 89 patients, the renal biopsy was performed within
three months of onset in 64 and showed normal or minimal
change appearances in all; 78 of 89 were followed up at Guy's
Hospital, and information was obtained on the remaining II
from their referring physicians.
Presentation (Table 1)
The age at presentation was equally distributed throughout
the ages from 15 to 82 (mean 42 19 SD); there was no excess
of younger patients. There was a slight male preponderance
(50:39), slightly greater in the younger patients, but this did not
reach significance at a 0.05 level. Eighty—five of the 89 patients
presented with a full nephrotic syndrome, and four with profuse
proteinuria not satisfying the definition of nephrotic syndrome
but with hypoalbuminemia and edema. The mean serum albu-
min was 19.7 g/liter (range 2 to 28 g/liter) and the mean
proteinuria was 10.2 gI24hr (range 1.2 to 40); the figures were
similar at all ages (some patients were oliguric from acute renal
failure).
Hypertension was present at presentation in 27 of 89 (30%) of
patients, less frequently in the younger group aged 15 to 30 (3 of
28 or 11%, P < 0.01). In nine patients there was severe
hypertension, with a diastolic blood pressure above 110 mm
Hg, but this was never observed in those aged less than 30 (P <
0.05).
One patient had macroscopic hematuria, and 21 of 74 patients
had microscopic hematuria on at least one occasion. This was
more frequent in patients aged more than 45 (13 of 32) than in
younger patients (7 of 41) (P < 0.05).
Renal function
The glomerular filtration rate (GFR) was decreased in 41 of 67
(61%) of those in whom measurements were available, and
severely depressed in 10 of 84 who had a plasma creatinine of
>250 mole/liter, or a GFR or creatinine clearance of less than
20 mliter/min. Diminished renal function was more rare in the
patients aged 30 to 45 at onset (P <0.05). Correspondingly nine
often of those with severely depressed renal function were aged
over 45 years; four subsequently regained normal renal func-
tion, but six required dialysis.
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Table 1. Characteristics of the patients at presentation.a
Age group 15—29 30-44 45—60 >60 Unknown Total
N 28 20 20 20 1 89
Age±sD 21±5 38±3 51±4 68±6 — 42±19
Male:Female 17:11 14:6 10:10 9:11 0:1 50:39 (1.3:1)
Mean serum albumin, glliter 18.8 20.0 18.2 22.4 — 19.7
range 11—38 2—32 8—27 6—38 — 2—38
Mean proteinuria, g/24 hr 9.0 12.0 10.1 10.5 — 10.2
range 1.2—22.5 3.0-40.0 1.8—25.5 2.0—20.0 — 1.2—40.0
Diastolic BP:
>95 mm Hg 3/28 9/20 8/20 7/20 — 27/89*
>110 mm Hg 0/28 4/20 3/20 2/20 — 9/89*
GFR or creatinine clearance < 80 mI/I .73 m2 14/22 5/15 9/14 13/16 — 41/67*
No. in acute renal failur&' 1/28 — 4/20 5/20 — 10/89*
Plasma creatinine, >130 p.mole/liter 3/26 6/16 8/14 9/18 — 26/74*
Microscopic hematuriac 3/25 4/16 7/16 6/16 I 21/74*
a Not all information was available on all patients; the denominators in the table indicate the shortfall.
b Some patients were in acute renal failure by the time of referral and hence had proteinuria below, and serum albumin in excess of the definitions
given in the Text.
Only one patient had macroscopic hematuria.
* P < 0.05 for the different age groups.
Prednisone
Pred- plus Aza-
nisone thioprine
Treatment N = 75 N = 4
Cyclophos-
phamideN = 2
None
N = 8
Lost proteinuria completely
Within 8 weeks 45 I I 0
Within 16 weeks 10 1 — 0
From 16—28 weeks 3 — — 0
Beyond 28 weeks — — — 6
AtAnyTime 58 2 1 6
Did not lose proteinuria completely
Partial remission 10 2 — I
Persistent nephrotic
syndrome 7 — 1 1
17 2 1 2
Initial treatment of the nephrotic syndrome (Table 2)
Only eight (9%) of the patients were never treated with
corticosteroid or cytotoxic drugs. Six of these eight eventually
went into remission, losing their proteinuria after a nephrotic
syndrome lasting for several months. All the remaining 81
patients were treated for their initial episode: 75 with predni-
sone alone, four with prednisone and azathioprine, and two
with cyclophosphamide.
Table 2 shows the response to this initial course of treatment.
The number of patients treated with prednisone and azathio-
prine (as part of a trial conducted in 1966 to 67) are too small to
be analyzed. All showed diminution of proteinuria, two losing
proteinuria altogether (the two patients receiving cyclophos-
phamide alone are considered below). Sixty—four of the 75
patients treated with prednisone alone as initial treatment were
given a mean of 13 weeks treatment (± SD 5, range eight to 20
weeks), but eleven patients received prolonged corticosteroid
treatment, often under the care of their own physicians, ranging
from 25 to 232 weeks.
A total of 45 patients went into remission within eight weeks
of starting treatment, and 55 within 16 weeks (with an estimate
Weeks from beginning of corticosteroid treatment
Fig. 1. Response of 75 adult—onset minimal change nephrotics to
treatment with oral corticosteroids. Symbols are: ( ) the cumula-
tive [511 percentage response for various periods after beginning
treatment, return of proteinuria to normal limits being the end—point; (A
age groups 15—29; (Lx) 30—44; (•) 45—59; (E) more than 60 years; and
(0—0) International Study of Kidney Disease in Children (ISKDC) [1,
50]. The response of the adults is slower and less than these children.
of 59% and 76% respectively, Fig. 1). In contrast, none of the
eight untreated patients did so (P < 0.005). There was no
significant influence of age on response to treatment (Fig. 1). Of
20 patients (27%) with continued proteinuria at 16 weeks, three
subsequently lost their proteinuria with no further treatment,
but ten showed a persistent minor proteinuria and seven had a
persistent nephrotic syndrome.
Duration of remission
The duration of remission was analyzed by the life table
method [51] in the 55 patients who achieved this within 16
weeks of starting corticosteroid treatment (Fig. 2); only 56%
were still free of proteinuria nine months later, and 34% after
two years. At this point 16 were still being followed and free of
Table 2. Initial treatment and response. 100
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proteinuria, but five of these 16 eventually relapsed, two of
them after five and seven years of complete remission.
Age at presentation did not influence the duration of remis-
sion (Fig. 2), however those with an early induction of remis-
sion (< eight week treatment) had earlier relapses (53% already
at nine months) in contrast to only 19% of those with later loss
of proteinuria (P < 0.05).
The three patients entering remission after the 16th week
never relapsed. Thus of all the 58 patients entering a full
remission under corticosteroids only 14 (24%) remained without
a relapsed at the end of the study. Three of these had been
followed more than five years and another three for more than
ten years.
Re/apses after cortico.steroid treatment (Table 3)
Relapses were seen in 44 of 58 patients who achieved
remission, the majority within the first year of follow—up. Here
there was an effect of age at presentation, since 29 of 34 (88%)
of those younger than 45 years relapsed, whereas only 14 of 23
(57%) older than this did so (P < 0.03). The total number of
relapses was also inversely related to age at presentation (P <
0.05, r —0.25). The total number of relapses varied from one
to eight (mean 1.7 1.8), 18 patients relapsing only once and 26
on more than one occasion. Only a small number of patients
satisfied the pediatric definitions 110, Iii of "steroid depen-
dent" or "frequent relapsers" [1—5] (13 of 44, 30%). Only six
were steroid dependent (14%) [13, 6]. No effect of age on this
aspect of behavior was noted (Table 3).
Treatment with cvclop/mosphamide (Table 4)
This was used in two patients as initial treatment and in 34
patients as secondary treatment, usually in a course of eight to
14 weeks with only three patients receiving prolonged courses
(16, 40 and 70 weeks). Four patients were given two courses of
cyclophosphamide, and one patient, three courses. A full
nephrotic syndrome was present at the start of treatment in 30
of the 36 patients. Of the two patients given cyclophosphamide
as initial treatment, one was epileptic and schizophrenic, the
other hypertensive with a single kidney. Only two of the
patients given cyclophosphamide as secondary treatment had
severe corticosteroid toxicity; one a duodenal ulcer and the
other steroid—induced myopathy. In the majority of patients the
drug was given for a multiple relapsing course (13), the devel-
opment of corticosteroid resistance (II) or dependency (10).
Several patients had more than one of these indications.
The immediate results of treatment with cyclophosphamide
are shown in Figure 3, 21 of 36 patients losing proteinuria within
eight weeks and 25 (69%) within 16 weeks. Four patients
showed a partial remission and only four a persisting nephrotic
syndrome, of whom three were older than 60 years, two having
developed acute renal failure during their initial episode; the
remaining patient died of a pulmonary embolus during the first
relapse. Eleven patients were treated with cyclophosphamide
together with prednisone and 25 with cyclophosphamide alone;
there was no difference in the number or timing of the induction
of remissions.
Age at presentations, degree of proteinuria or pattern of
relapse did not affect the immediate results of treatment.
However, those with rapid induction of remission with
corticosteroids (less than eight weeks) also showed rapid induc-
tion of remission with cyclophosphamide (within eight weeks)
more frequently than those slower to respond to corticosteroids
(14 of 19 vs. 5 of 15) respectively (P < 0.05).
The duration of remission was longer after treatment with
cyclophosphamide than with prednisone (Fig. 4), only 13 of 32
responders treated with cyclophosphamide relapsing compared
with 44 of 58 treated with prednisone (P <0.01). Two thirds of
the cyclophosphamide—treated patients were still in remission
four years after treatment. Of 16 followed up beyond this point,
only one further patient relapsed. There was no effect of age at
presentation or pattern of relapses on the duration of remission,
but the numbers in each group are small.
However, a tendency for a shorter remission period was
noted in those with a previous history of multiple relapses,
particularly if steroid dependent (45% having relapsed at 15
months).
Status at last follow—up
The mean follow—up from onset until January 1983 was 91
63 months, range I to 24 years in surviving patients; 30 patients
had been followed for more than 10 years. Fifteen of the 89
(17%) patients had died (Table 5), giving a survival of 64% at 24
years. All patients who died were over 42 years of age at onset.
The majority were over 60 years; these older patients had a
significantly higher mortality than their younger counterparts,
in excess of that expected for age (Fig. 5). Eleven patients died
within three years of onset, one in chronic uremia and another
four from complications related to the nephrotic syndrome:
acute renal failure in two, a pulmonary embolus and a myocar-
dial infarct in one. All other deaths were from apparently
unrelated causes, seven patients being in complete remission at
the time. Of four patients dying from a malignant tumour, one
had been treated with cyclophosphamide nine years previously
and another with azathioprine three years before. Of the
surviving 74 patients, 59 (80%) were in complete remission, ten
had persisting proteinuria and only five (7%) a persisting
nephrotic syndrome. The proportion of living patients in com-
plete remission was 61% at one year and 90% at 15 years.
Fourteen percent of patients had evidence of some renal
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Fig. 2. Stability of response to corticosteroid treatment in 55 patients
who went into coin p/etc remission during the first /6 weeks' after
beginning treatment. (See Fig. I for symbols).
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Age at presentation 15—29 30—44 45—59 60 years ? Total
No. of patients relapsing 17 12 8 6 1 44
single 7 3 4 4 — 18
multiple 10 9 4 2 1 26
Characteristic pattern of relapses
Frequent relapses 3 1 2 1 — 7
Steroid dependentb
Relapsed once on steroidsc
2
2 J
2 1.
5 J
—
4 J
I 110 J
1
0 .11 6 17II I
Occasional relapse 10 4 2 4 20
The birth date of one patient was not known with accuracy.
b Steroid dependent is used as by the ISKDC.
Relapsed on steroids indicates only one relapse while taking steroids which does not satisfy the definition of the ISKDC for steroid dependency
but probably indicates a similar tendency.
duced myopathy and two patients developed pulmonary edema
during volume replacement, fatal in one anuric patient (aged
82). No patients showed cyclophosphamide toxicity apart from
reversible leukopenia and mild hair loss in some patients.
A total of 11 pregnancies occurred in five patients, all in
remission, four of whom had previously been treated with
cyclophosphamide, All pregnancies ran an uneventful course
Table 4. Reasons for treatment with cyclophosphamide.
N Subtotal Subtotal
In initial episode of nephrotic syndrome
As primary treatment
Because of resistance to corticosteroids
2 9
in initial episode 7
After relapse
In first relapse 14
Because of resistance to
corticosteroids 4
Because relapse occurred while
taking steroids 7 27
Other 3
In subsequent relapse 13
Dependence upon corticosteroids S
Frequent relapses 4
Other 4
Total 36
100
80
60
40
20
C0
cci0)
E
ci)
C
ci)
>
E
0
100
80
60
40
20
C0
cci
cc,
E
ci)
ci)
ci)
0.
E0
cc
C
ci)
>
Co
E
0
0 5 10 15
Years from remission
Fig. 4. Stability of response to cyclophosphamide in 28 patients who
lost proteinuria completely following treatment with cyclophosphamide
(—•), compared with 55 patients who lost proteinuria completely
following corticosteroid treatment (....). The response following
cyclophosphamide is significantly more stable.
ment of renal function (nos. 1, 3,4, 6, 7, and 16—20). All were
over 45 years of age, four having recovered from episodes of
acute renal failure during their initial attack. Only one of the
remainder had always been corticosteroid—responsive. Five of
these ten patients died still proteinuric.
Complications of the nephrotic syndrome were noted in 19
patients: thrombosis in 12 patients (deep vein thrombosis in
eight, pulmonary embolism in three, femoral arterial thrombo-
sis in one); major infection in ten patients (cellulitis in three,
pneumococcal peritonitis in one, pneumonia in three and other
28 sepsis in three); acute renal failure in ten, requiring dialysis in
eight; and two myocardial infarctions (in two males aged 49 and
69) probably no greater than expected for the population at risk.
Complications of treatment apart from the sepsis just noted,
included a duodenal ulcer in one patient, vertebral collapse in
another, and psychosis in a third. Two patients had steroid—in-
024 8 16
Weeks from starting treatment
Fig. 3. Time to complete loss of proteinuria in 36 adult-onset nephrotic
patients with minimal changes treated with cyclophosphamide. Sym-
bols are: all the patients ( ); (----) those treated concomitantly
with prednisone (N = 11); and (•—•) those treated with cyclophos-
phamide alone (N = 25).
impairment and 21% had hypertension, present also in those in
complete remission. In contrast, those with impaired renal
function had in general persistent disease. Table 5 summarizes
the characteristics of the ten patients with persistent impair-
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Table 5. Patients who died during follow—up or who showed persistent reduced renal function.
Follow— Onset
Age at up, GFR,
No. Onset Sex mths mi/mm Prednisone Relapsed
Death probably related to nephrotic syndrome or its treatment
I. 61 f 20 40 no —
2. 82 m 0.5 ARF not treated
3. 64 f 6 ARF no — no
4 69 m 36 18 no
5. 71 m 8 17 yes
Death probably unrelated to nephrotic syndrome or its treatment
6. 54 m 6 ARF no
7. 63 m 10 37 yes
8. 42 m 190 90 no
9. 71 f 129 urea 9 not treated
liter
10. 47 f 123 71
II. 64 m 36 creat.
106
smole/
liter
12. 43 m 108 43
13. 73 f 24 51
14. 55 m 10 53
15. 79 f 5 34
Additional living patients with reduced renal function
16. 45 m 144 ARF no
17. 72 f 83 51 not treated
18. 58 f 84 55
19b 49 m 134 24
20.c 74 m 16 ARF
Renal status at last
follow—up or at death
Cause of death Function Proteinuria
pulmonary edema after
albumin infusion
dementia, inanation,
uremia
— myocardial infarction
pulmonary embolus
proteinuria
GFR 40 remission
creatinine 150 remission
smole/liter
GFR 50 remission
GFR 41 remission
creatinine 370 nephrotic
smole/liter
without proteinuria and with normal deliveries of healthy
babies, except for a single pregnancy which ended in sponta-
neous abortion.
Discussion
Minimal change disease ("lipoid nephrosis") is the most
frequent single cause of the nephrotic syndrome in man. The
majority of cases occur during childhood, comprising 94% of
those aged less than six years at onset, and 59% of those aged
more than six but less than 15 [1]. In adults, up to 30% of cases
have minimal changes on biopsy [19, 20]. The proportion is
similar up to over 60 years of age [29, 301, with a mean age of
onset about 40 years; one quarter of our patients were aged
more than 60 years. Although there is a very large recorded
experience of childhood onset cases, the question was whether
we can expect the same evolution in a three—year—old child, a
young adult or an 80-year—old. What influence of age is there on
response to corticosteroids, frequency of relapse, or response
to cytotoxic drugs? We have shown previously that within the
childhood group, the frequency of relapses is strongly related to
age at onset [48], the younger patients having a much more
frequent multiple relapsing course. We were not, however, able
to confirm suggestions [31], that the presence of 1gM made a
difference to behaviour, either in children or in adults [27].
The characteristics of our patients at presentation are similar
to those reported previously [16—241: a male:female ratio of
1.3:1, only 6% with a serum albumin below 10 g/liter, 30% with
hypertension, 28% with occasional microscopic hematuria and
60% with impairment of renal function. However, our older
patients (> 60 years at onset) had a greater incidence of
hypertension and severe impairment of renal function. The
degree of hypoalbuminemia and severity of proteinuria were
not affected by age. These results contrast with similar
nephrotics of childhood onset [1, 32, 33] in that children have a
lower incidence of hypertension [9 to 14%] and impaired renal
function (10 to 14%). Children also have more severe
hypoalbuminemia, 38% having a serum albumin of less than 10
g/liter [32]. Further, a presentation in established acute renal
failure is almost confined to older adults [33, 34], although a few
children have been described [35], including four from our own
Response to treatment
Cyclophos-
phamide
no uremia
mmole/
urea 27
mmole/liter
on dialysis
on dialysis
"renal failure"
normal
creatinine 200
smole/liter
creatinine 180
smole/liter
normal
normal
normal
nephrotic
nephrotic
proteinuria
remission
nephrotic
remission
yes
no
yes
yes
yes
yes
once no
— — carcinoma pancreas
twice — ruptured septal
aneurysm
multiple — ruptured aortic
aneurysm
— — left ventricular failure
once yes carcinoma colon
— — lymphosarcoma
— — pulmonary edema
once — carcinoma pancreas
— — ?cause
— — intestinal obstruction
no
multiple yes
— no
— — no
remission
remission
? remission
7 proteinuria
? remission
? remission
yes
no
a Also had vertebral collapse from prolonged corticosteroid treatment.
b Had a myocardial infarct.
C Had a kidney removed 20 years earlier for carcinoma.
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Years from apparent onset
Fig. 5. Survival of( ) 89 adult patients aged 15 1o82 (mean 42
years) at onset. The survival of those aged over 60 (U—LI), N = 20, at
onset is significantly less than those aged 15 to 59 at onset (U—U), N =
68 (P < 0.0001). This analysis is based on only 88 patients, since the
exact age of one patient was not known.
series [36]. Thus, only the incidence of persistent microscopic
hematuria and the absence of many granular casts from the
urine can help distinguish adult—onset patients with minimal
changes from their fellow sufferers with other forms of glomer-
ular pathology. We have shown previously [21] that, in contrast
to children, only about half the adult—onset patients with
minimal changes show highly selective patterns of proteinuria.
The clinical evolution of minimal change nephrotics, either
children or adults, appears to be that of a self—limiting disorder.
The majority of our untreated patients eventually entered
remission (6 of 8) similar to the result of the British Medical
Research Council trial [37] in which 12 of 17 controls remitted
spontaneously, and the Interhospitals study in the United
States in which 5 of 12 control patients remitted [19]. However,
one of our untreated patients died, and three of the control
group in the Interhospitals study had to be treated because of
severe hypotension and pre-renal azotemia [19]. Clearly these
untreated patients are at risk from the many complications of
the nephrotic syndrome, while corticosteroid treatment greatly
accelerates the remission, even though at a rather slower rate in
adults than in children.
In children, 93% enter complete remission with disappear-
ance of proteinuria during eight weeks treatment [1, 3, 5], only
4.2% remitting later. In contrast, the final estimate was that
although 81% of our adult—onset patients achieve complete
remission, as described by others [16—241, only 60% reached
this state by eight weeks and 76% by 16 weeks. This lower (and
slower) response to treatment was not related to age at onset. In
children 60% of early non-responders subsequently entered
remission [I, 3—5], and again in our adults, 43% (13 of 30) of
those not in remission by eight weeks lost proteinuria subse-
quently. This slower response of our adult-onset patients may
represent an effect of lower corticosteroid dosage in relation to
body size rather than a real difference in sensitivity to cortico-
steroids. Children usually receive about 60 mg/m2/24hr, for up
to four weeks [3, 4, 5] which is equivalent to 100 mg/24hr or
more for most adults.
After entering remission the majority of our patients re-
lapsed, almost all within one or two years of onset; only 24%
had sustained remission without any relapses. This pattern is
similar to that in children, and we could only detect an effect of
age on the duration of remission in that 88% of younger adults
relapsed within the first nine months after remission, compared
with 60% of older adults. Those who responded rapidly to
corticosteroids appeared to relapse earlier. The number of
relapses in our adult—onset population was lower than that
reported in children, 1.7/patient compared with the 7.3/patient
calculated from the data of Siegel et al [9]. The number of
relapses was also lower with increasing age. Similar results
were reported by Zech et at [30] in whose series none of 14
adult-onset minimal change nephrotics aged over 60 relapsed
during follow—up, averaging 14 months. When the overall
pattern of relapses is compared with that seen in children,
differences emerge. In children, 39 to 55% show a frequent
relapsing pattern [6—10, 38, 39], compared with only 21% in our
series, of whom half showed corticosteroid dependence. About
half our patients showed one or very infrequent relapses, while
24% (a similar proportion to childhood-onset series) never
relapsed.
In children with a multiple—relapsing course, corticosteroid
toxicity or resistance to corticosteroid treatment short courses
of cyclophosphamide [4, 10, 12, 40] or chlorambucil [13—15, 41]
have been used with apparent benefit. Controlled studies indi-
cate that although 60% of children treated with cyclophospham-
ide are still in remission after two years, only 40% are still in
remission at five years [4, 10, 12, 40]; the benefit was least for
those with corticosteroid dependence [10, 11]. Better results
were obtained with long, potentially toxic courses of
chlorambucil (12 mg/kg total dose) [13—15], whether the patients
were corticosteroid dependent or not; 87% remained in remis-
sion at two years and 80% at five years. However, when lower
doses believed to be less toxic were employed [10], similar
results to those with cyclophosphamide were obtained.
In contrast to the wealth of information on the response of
children with minimal change disease to cytotoxic agents, there
are few data on similar adults. Coggins, in his recent review of
the literature [21], identified only 31 patients treated with
cyclophosphamide out of a total of 232 adults with a minimal
change nephrotic syndrome. The duration of remission has not
been studied in any detail. In our 36 patients treated with
cyclophosphamide, 70% of patients went into remission by 16
weeks, and there was no difference between those given or not
given concomitant corticosteroid therapy. A more rapid re-
sponse to cyclophosphamide was obtained in those patients
who had responded rapidly to corticosteroids, suggesting that
common characteristics determine the response to both agents.
The subsequent duration of remission, however, was superior
to that induced by corticosteroids in adults or children, or
cyclophosphamide in children; 62.5% of our cyclophospham-
ide—treated patients were still in remission ten years later.
There was some suggestion that a previous multiple—relapsing
course resulted in shorter remissions, but this did not reach
significance for the numbers tested. One third of our patients
received cyclosphosphamide during only their first relapse, and
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nine during their initial episode, which may account at least in
part for the superior results when compared to childhood series.
Only 6% of our patients had a persistence of a nephrotic
syndrome when last seen (mean 7.5 years follow-up), but the
outcome appeared worse for older patients compared with
younger ones. The survival of patients over 60 at onset was only
50% at ten years, although most of these deaths were in patients
presenting ten or more years ago. Only five out of 15 deaths in
older nephrotics could be related to complications of their
nephrotic syndrome, but in contrast to Coggins' data [211 only
one died of a treatment—related complication (pulmonary edema
in an anuric patient); and only one death was related to
infection, in a patient in complete remission and not receiving
steroids at the time.
Only one patient went into chronic terminal uremia, whose
nephrotic syndrome had been resistant to corticosteroids from
outset and who did not have a repeat biopsy. A number of other
older patients had evidence of renal impairment (allowing for
age) when last seen. This evolution was also related to cortico-
steroid resistance and prolonged proteinuria. Half of these
patients originally presented in acute renal failure, itself asso-
ciated with a high mortality in the initial illness as we have
reported elsewhere and in agreement with others [42, 431.
Progression of initially corticosteroid—responsive, minimal
change patients to renal insufficiency is very rare, although
several cases have been recorded [16—18], often associated with
the appearance of focal segmental scierosing lesions in later
biopsies.
A number of our patients suffered complications of the
nephrotic state [44]. Thrombosis [45] was present at least once
in 13% of our patients, being the cause of death in one
(pulmonary embolus). All but a single episode of femoral
arterial thrombosis were venous. Only two patients had a
myocardial infarction, but the incidence of vascular disease in
this group of patients may be low because of the temporary
nature of their nephrotic syndrome, as we have discussed
elsewhere [46]. One patient who suffered an infarct had had
prolonged proteinuria and also a prolonged corticosteroid treat-
ment which resulted in vertebral collapse. Severe infections
were seen in 12% of the patients, one of which was a case of
pneumococcal peritonitis in a 21—year—old man; otherwise this
complication is almost confined to childhood—onset patients
[44]. Of four patients who developed tumors, one had received
cyclophosphamide and one azathioprine, but it is impossible to
say if this represents coincidence or effect [47]. Sterility was not
induced by cyclophosphamide in all females, in that five of them
produced a total of 11 children subsequently. However tests of
gonadal function were not performed in the males [48]. In
patients over the age of 60 years, it seems reasonable to use
cyclophosphamide as primary treatment [49], in view of the
devastating effect of the nephrotic syndrome in the aged and the
prolonged remission obtained.
Thus the principal differences between the nephrotic syn-
drome with minimal changes as seen in adults, when compared
with children, lies in the higher incidence of hypertension and
renal impairment in the adults, amounting at times to acute
renal failure. Adults respond more slowly and less completely
to both corticosteroids and cyclophosphamide than children,
although lower doses of prednisone are in use in most adult
clinics. Relapses are less frequent in adults, and stable remis-
sion more frequently attained after cyclosphosphamide treat-
ment. These data have implications for policy with regard to
renal biopsy in nephrotic adults, especially the elderly [25, 26].
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